Overview

BEGIN Novel ImagiNG Biomarkers

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Phase:
Phase 4
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
University of Iowa
University of Kansas
University of Virginia